thromboxane-a2 has been researched along with Bronchial-Spasm* in 21 studies
4 review(s) available for thromboxane-a2 and Bronchial-Spasm
Article | Year |
---|---|
The role of thromboxane A2 in the pathogenesis of airway hyperresponsiveness.
Topics: Animals; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Humans; Thromboxane A2 | 1989 |
[Various mechanisms of bronchial hyperreactivity].
Topics: Asthma; Autonomic Nervous System; Bronchi; Bronchial Spasm; Humans; Prostaglandins; Thromboxane A2 | 1988 |
Overview of physiological and pathophysiological effects of thromboxane A2.
Thromboxane (Tx) A2 is a biologically potent and chemically unstable metabolite of prostaglandin endoperoxides. Recent developments in measurement techniques and the availability of both selective inhibitors of Tx synthetase and TxA2 receptor antagonists have facilitated the implication of TxA2 as a physiological modulator and as a mediator in thrombotic, vasospastic, and bronchospastic conditions. TxA2 is synthesized by platelets and contributes to platelet activation and irreversible platelet aggregation in physiological hemostasis and in thrombosis (e.g., unstable angina, stroke). TxA2 is also synthesized in intestinal, pulmonary, and renal tissues by cells other than platelets. Particularly in these tissues, TxA2 appears to act as a physiological modulator of changes in blood flow distribution and airway caliber. Strong stimuli for TxA2 release from these tissues may initiate ulcer, pulmonary hypertension, bronchoconstriction, and renal vasoconstriction. Evidence supports participation of TxA2 and/or TxA2 receptors in modulation of natural cytotoxic cell cytotoxicity, in tumor growth and metastasis, in complications of pregnancy (e.g., preeclampsia), and in the progression of ischemic injury after coronary artery occlusion. This evidence supports pivotal involvement of TxA2 in pathophysiology and provides a strong rationale for pursuing TxA2-blocking strategies in drug development. Topics: Animals; Blood Platelets; Bronchial Spasm; Cardiovascular Diseases; Hemostasis; Humans; Muscle Contraction; Muscle, Smooth; Platelet Aggregation; Prostaglandin Endoperoxides; Receptors, Prostaglandin; Receptors, Thromboxane; Thrombosis; Thromboxane A2; Thromboxane-A Synthase; Vasoconstriction | 1987 |
[Role of arachidonic acid (ETE) and its metabolites in the pathogenesis of bronchial spasm. I. Metabolites formed under the effect of cyclooxygenase].
Topics: 5,8,11,14-Eicosatetraynoic Acid; Bronchi; Bronchial Spasm; Fatty Acids, Unsaturated; Humans; Muscle, Smooth; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Prostaglandins F; Thromboxane A2 | 1983 |
1 trial(s) available for thromboxane-a2 and Bronchial-Spasm
Article | Year |
---|---|
Thromboxane biosynthesis in allergen-induced bronchospasm. Evidence for platelet activation.
To determine if platelet activation occurs after allergen inhalation in atopic asthmatics, we measured two urinary metabolites of the principal cyclooxygenase product of platelets, thromboxane A2 (TxA2), using the sensitive and specific technique of gas chromatography-negative ion, chemical ionization-mass spectrometry. Seven atopic asthmatics underwent allergen challenge after low dose aspirin to suppress platelet thromboxane generation and on placebo days. On placebo days, the urinary levels of 2,3-dinor-TxB2 increased from 76 +/- 22 pg/mg creatinine to 216 +/- 95 after allergen, and 11-dehydro-TxB2 from 396 +/- 98 to 627 +/- 137 (p less than 0.05). Low dose aspirin suppressed excretion of urinary thromboxane metabolites and prevented the rise after allergen inhalation without altering the bronchoconstriction. Excretion of 2,3-dinor-6-keto-PGF1 alpha, a metabolite of prostacyclin, was unaltered by this aspirin regimen. We conclude that platelets are activated after allergen challenge, but that platelet-derived TxA2 is not important in the early bronchoconstrictor response. Topics: 6-Ketoprostaglandin F1 alpha; Adult; Allergens; Aspirin; Blood Platelets; Bronchial Spasm; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Female; Forced Expiratory Volume; Gas Chromatography-Mass Spectrometry; Humans; Male; Placebos; Platelet Activation; Thromboxane A2; Thromboxane B2 | 1989 |
16 other study(ies) available for thromboxane-a2 and Bronchial-Spasm
Article | Year |
---|---|
The induction of a biphasic bronchospasm by the ETB agonist, IRL 1620, due to thromboxane A2 generation and endothelin-1 release in guinea-pigs.
1. IRL 1620 (0.01-0.1 mg kg-1, i.v.), a selective endothelin B (ETB) receptor agonist, induced a dose-dependent biphasic increase in total lung resistance and a decrease in dynamic compliance in anaesthetized and artificially ventilated guinea-pigs. After intravenous injection of IRL 1620 (0.03 mg kg-1), the first phase was observed within 2 min whereas the second phase started between 5 and 10 min after injection and was long lasting. 2. In order to characterize which endothelin receptors are involved in both phases of bronchoconstriction, we studied the effect of ETA and ETB receptor antagonists (BQ 123 and BQ 788, respectively). BQ 788 (0.1-1 mg kg-1, i.v.) inhibited, in a dose-dependent manner, both phases of bronchoconstriction. BQ 123 (3 mg kg-1, i.v.) markedly inhibited (by 76%) the second phase of bronchoconstriction but had no effect on the early component of the response. 3. The effect of atropine, neurokinin-I (NK1) and neurokinin-2 (NK2) receptor antagonists (SR140333 and SR48968, respectively) were tested to investigate the possible involvement of cholinergic and sensory nerve activation, respectively, in the response to IRL 1620. Likewise, the role of arachidonic acid metabolites (leukotriene D4 antagonist, ONO-1078 and thromboxane A2 (TXA2) inhibitor, OKY-046) in this response was also investigated. OKY-046 (1 mg kg-1, i.v.) and atropine (1 mg kg-1, i.v.) partially inhibited the first phase (by 80% and 20%, respectively) without affecting the late phase of bronchoconstriction. Neither ONO-1078 (1 mg kg-1, i.v.) nor the combination of SR140333 (0.2 mg kg-1, i.v.) and SR 48968 (0.2 mg kg-1, i.v.) modified IRL 1620-induced bronchoconstriction. 4. A low dose of IRL 1620 (0.005 mg kg-1, i.v.) induced a monophasic bronchoconstriction. Pretreatment by phosphoramidon (100 mumol kg-1, i.v.) restored the second phase of bronchoconstriction. In this condition, BQ 123 (3 mg kg-1, i.v.) was able to inhibit partially the second phase of bronchoconstriction. 5. These results suggest that both phases of bronchoconstriction induced by IRL 1620 were mediated primarily by ETB receptor activation, the first phase being a consequence of TXA2 and acetylcholine release. The inhibition by an ETA receptor antagonist and the restoration by a neutral endopeptidase (NEP) inhibitor of the second phase of bronchoconstriction suggests that primary activation of ETB receptors leads to autocrine/paracrine endothelin-1 (ET-1) release that would subsequently cause profound b Topics: Animals; Atropine; Bronchial Spasm; Bronchodilator Agents; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Female; Guinea Pigs; In Vitro Techniques; Male; Methacrylates; Neurokinin-1 Receptor Antagonists; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Receptors, Endothelin; Receptors, Neurokinin-2; Thromboxane A2; Thromboxane-A Synthase | 1996 |
Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs.
A novel chemical compound, DT-TX 30 SE (E-6-(4-2-(4-chlorobenzenesulphonylamino)-ethyl)phenyl)-6-(3-pyrid yl)- hex-5-enoic acid), was studied in various models of guinea pig pulmonary function. The compound was a potent inhibitor (ED50 0.019 mg/kg, i.v.) of bronchospasm induced by the thromboxane receptor agonist U-46619, indicating thromboxane receptor antagonism. At even lower doses (ED50 0.0036 mg/kg, i.v.), it blocked arachidonic acid-induced bronchospasm. Interpretation of the latter results as evidence for additional thromboxane synthetase inhibitory activity was supported by the inhibition of arachidonic acid- or bradykinin-induced thromboxane B2 production in an isolated lung preparation, although prostaglandin E2 and prostaglandin 6-oxo-F(1 alpha) production measured at the same time were not inhibited. The potency of DT-TX 30 SE was compared with thromboxane receptor antagonists and synthetase inhibitors described in the literature. As a receptor antagonist, DT-TX 30 SE was significantly more potent than BM 13505 and BM 13177 (assessed by antagonism of U-46619-induced bronchospasm), but less potent than SQ 29548, while as a thromboxane synthetase inhibitor, it was significantly more potent than OKY 046 and UK 37248 as assessed by antagonism of arachidonic acid-induced bronchospasm or (OKY 046) inhibition of thromboxane production in isolated lung. The compound was active by the oral route as shown by its ability, at 10 mg/kg, p.o., to significantly reduce the immediate allergic response of sensitized guinea pigs to an ovalbumin aerosol. Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Arachidonic Acid; Bronchial Spasm; Dinoprostone; Enzyme Inhibitors; Fatty Acids, Unsaturated; Guinea Pigs; Lung; Male; Prostaglandin Endoperoxides, Synthetic; Pyridines; Receptors, Thromboxane; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase | 1996 |
Effects of 1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3- (1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid with thromboxane A2 synthetase inhibitory and H1-blocking activities on anaphylactic bronchospasm.
1-[3-(4-Benzhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl )- 1H-indole-6-carboxylic acid (CAS 172544-75-1, KY-234) was characterized pharmacologically. KY-234 (10(-9)-10(-6) mol/l) and ozagrel (10(-8)-10(-5) mol/l) inhibited the production of thromboxane A2 (TXA2) in rabbit platelets. KY-234 and pyrilamine at concentrations of 10(-9)-10(-6) mol/l relaxed the isolated guinea pig trachea contracted with histamine, while neither drug attenuated the heart rate increased by histamine. Cimetidine antagonized histamine in the right atrium but not in the trachea. KY-234 (10(-8)-10(-5) mol/l) and ozagrel (10(-7)-10(-4) mol/l), but not pyrilamine, attenuated the contraction induced by leukotriene D4 (LTD4) and platelet-activating factor in the lung parenchymal strips. In anesthetized guinea pigs, KY-234 (1-10 mg/kg p.o.) inhibited the LTD4- and histamine-induced bronchoconstriction. Ozagrel and terfenadine inhibited only the LTD4- and histamine-induced constrictions. KY-234 (3-30 mg/kg p.o.) inhibited the anaphylactic bronchoconstriction continuously for 15 min after antigen-challenge. Terfenadine (3-30 mg/kg p.o.) inhibited the constriction more strongly within the first 5 min (fast phase) than it did within 5 to 15 min (slow phase) after the challenge. Ozagrel (100 mg/kg p.o.) slightly attenuated only the constriction during the slow phase. These findings demonstrated that KY-234 has a selective TXA2 synthetase-inhibitory and H1-blocking activity and protects against anaphylactic bronchospasm more effectively than a TXA2 synthetase inhibitor or H1-blocker alone. Topics: Anaphylaxis; Animals; Bronchial Spasm; Bronchoconstriction; Enzyme Inhibitors; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Indoles; Leukotriene D4; Lung; Male; Methacrylates; Platelet Activating Factor; Rabbits; Thromboxane A2; Thromboxane-A Synthase; Trachea | 1996 |
Airway hyper- or hyporeactivity to inhaled spasmogens 24 h after ovalbumin challenge of sensitized guinea-pigs.
1. The aim of this study was to determine whether an inhalation of ovalbumin (OA, 10 or 20 mg ml-1) by conscious OA-sensitized guinea-pigs leads to airway hyperreactivity to spasmogens 24 h later. In contrast to most previous studies, the spasmogens (5-HT, methacholine (MCh), U-46619 and adenosine) were administered by inhalation and airway function was measured in conscious guinea-pigs. 2. Guinea-pigs were sensitized by i.p. injection of 10 micrograms OA and 100 mg aluminium hydroxide in 1 ml normal saline; 14-21 days later they were exposed to an inhalation of 5-HT, MCh, U-46619 or adenosine. Specific airway conductance (sGaw) was measured in conscious animals by whole body plethysmography. The spasmogens caused bronchoconstriction, measured as a reduction in sGaw from the pre-inhalation basal values. Dose-related bronchoconstrictions were observed with 5-HT, MCh and U-46619. 3. The effect of an ovalbumin macroshock challenge upon the responses to each spasmogen were examined by giving an inhalation of aerosolized OA at 24 h (or 7 days in the cause of adenosine) after an initial spasmogen challenge. Eighteen to twenty-four hours after the OA macroshock, the same guinea-pigs were exposed to a repeated inhalation of 5-HT, MCh, U-46619 or adenosine. 4. U-46619 was the only spasmogen to demonstrate hyperresponsiveness, the peak change in sGaw being increased from -12.3 +/- 9.9 to -38.8 +/- 5.0% by 10 mg ml-1 OA challenge. In contrast, the ovalbumin challenge (20 mg ml-1) inhibited the bronchoconstrictions to 5-HT (50 micrograms ml-1) and MCh (100 micrograms ml-1). Adenosine demonstrated bronchoconstriction in sensitized guinea-pigs but no significant change in the response was observed after an OA challenge. 5. All results were compared with a control group of sensitized guinea-pigs receiving a NaCl challenge. The bronchoconstrictor responses to 5-HT, MCh, U-46619 or adenosine did not differ significantly before and after the saline challenge, indicating reproducibility of the responses. 6. In further experiments, guinea-pigs were exposed to inhalation of 5-HT (50 micrograms ml-1) or MCh (300 micrograms ml-1) 24 h before atropine (10 micrograms, 100 micrograms or 1 mg ml-1) and again at 0.5 to 1.5 h afterwards. Atropine, antagonized the 5-HT- and MCh-induced bronchoconstrictions over the same antagonist dose-range. This suggests that the bronchoconstriction induced in the conscious guinea-pig by 5-HT is mediated primarily via muscarinic receptors, possibly Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine; Administration, Inhalation; Airway Resistance; Animals; Asthma; Atropine; Bronchial Spasm; Bronchoconstrictor Agents; Bronchodilator Agents; Dose-Response Relationship, Drug; Guinea Pigs; Histamine; Male; Methacholine Chloride; Ovalbumin; Plethysmography, Whole Body; Prostaglandin Endoperoxides, Synthetic; Thromboxane A2; Vasoconstrictor Agents; Vasodilator Agents | 1995 |
Role of thromboxane receptor activation in the bronchospastic response to endothelin.
The selective TxA2/PGH2 (TP) receptor antagonist, SQ 30,741, was used to test the hypothesis that TP-receptor activation contributes to the reactivity of airways and isolated trachea to endothelin-1 (ET-1). Dose-dependent contractions of guinea pig tracheal strips to ET-1 in vitro were unaffected by either SQ 30,741 (1 microM) or indomethacin (2.8 microM). In contrast, maximal bronchospastic responses (increases in airways resistance and decreases in dynamic lung compliance) of anesthetized guinea pigs to ET-1 (0.5 and 1.5 nmole/kg i.v.) in vivo were blocked greater than 90% by SQ 30,741 (1 mg/kg i.v.). Concurrent increases in arterial blood pressure and decreases in leukocyte counts induced by ET-1 were unaffected by SQ 30,741. In rats, ET-1 (1.5 nmole/kg i.v.) did not affect lung mechanics, but did cause biphasic blood pressure and leukopenia responses which were unaltered by SQ 30,741. These data demonstrate that there is considerable species variability in the bronchospastic response to ET-1, and that in guinea pigs, this response is caused predominantly by the activation of TP-receptors. Topics: Animals; Bronchial Spasm; Endothelins; Guinea Pigs; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Peptides; Rats; Rats, Inbred Strains; Receptors, Prostaglandin; Receptors, Thromboxane; Thromboxane A2; Thromboxanes; Trachea | 1990 |
Role of thromboxane receptors in Forssman shock in guinea pigs.
Forssman shock is a bronchospastic reaction mounted in guinea pigs on intravenous administration of an antiserum obtained from rabbits immunized against sheep erythrocytes. The involvement of thromboxane receptors in Forssman shock was determined with SQ 30,741, which was characterized as a selective antagonist of these receptors in guinea pig airways in vitro and in vivo. A volume of antiserum producing consistent, sublethal bronchoconstriction was given either alone (control) or 3 min after SQ 30,741 (0.03, 0.3, or 1.0 mg/kg iv) to urethan-anesthetized guinea pigs. In controls, maximum reductions in dynamic compliance (-59 +/- 6%, P less than 0.01) and increases in airways resistance (383 +/- 97%, P less than 0.01) were detected 1 min after antiserum. Both responses were significantly inhibited by SQ 30,741, either partially at 0.03 mg/kg or completely at 0.3 mg/kg. An accompanying thrombocytopenia was not abated by SQ 30,741. In separate experiments, bronchospasm was reduced by aerosol administration of 0.1% SQ 30,741 and completely prevented by aspirin (10 mg/kg iv). When Forssman antiserum was injected in lethal quantities to other guinea pigs, SQ 30,741 (1 mg/kg iv) attentuated only the resistance component of bronchospasm and did not prevent death. These data demonstrate that thromboxane receptor stimulation is a pivotal step in the pulmonary manifestations of sublethal Forssman shock but is less crucial in more severe forms of the reaction. Topics: Animals; Antigens, Heterophile; Bronchial Spasm; Forssman Antigen; Guinea Pigs; Male; Receptors, Prostaglandin; Receptors, Thromboxane; Shock; Thromboxane A2; Trachea | 1989 |
LG 30435, a new potential antiasthmatic agent.
LG 30435 is a new quarternary phenothiazine derivative with H1-antihistaminic and antimuscarinic properties. The ability of LG 30435 to prevent changes in respiratory mechanics, induced by different mediators and the immunological reaction, was monitored together with biological and radioimmunological determination of circulating thromboxane-A2 (TxA2) in anaesthetized guinea-pigs. LG 30435 dose-dependently reduces the bronchoconstriction and TxA2 generation caused by different stimuli such as histamine, acetylcholine, leukotriene C4 (LTC4) and PAF-acether. In addition i.v. and aerosol administration of LG 30435 causes a dose-dependent reduction of the increase in airway resistance and TxA2 generation induced by ovalbumin challenge in actively sensitized animals. LG 30435 infused at different concentrations through the isolated guinea-pig lungs inhibits the TxB2 generation caused by different anaphylactic mediators, but not by arachidonic acid. These data, which further substantiate the bronchodilator activity of LG 30435 against a variety of stimuli and demonstrate its protective properties on lung anaphylaxis, suggest that this compound has a potential therapeutic value in the treatment of asthma. Topics: Anaphylaxis; Animals; Asthma; Bronchial Spasm; Bronchodilator Agents; Dose-Response Relationship, Drug; Guinea Pigs; Male; Phenothiazines; Respiratory Mechanics; Thromboxane A2 | 1989 |
Effects of inflammatory mediators on neuromuscular transmission in canine trachea in vitro.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Bronchial Spasm; Dogs; In Vitro Techniques; Leukotriene B4; Muscle, Smooth; Ozone; Platelet Activating Factor; Prostaglandin Endoperoxides, Synthetic; SRS-A; Synaptic Transmission; Thromboxane A2; Trachea | 1988 |
Pharmacological modulation of platelet activating factor (PAF)-induced bronchoconstriction and hypertension in anaesthetized guinea-pigs.
The effect of PAF has been examined in anaesthetized guinea-pigs. Intravenous (i.v.) administration of PAF (10 ng kg-1) did not modify the respiratory response but decreased the arterial blood pressure. A high dose of PAF (200 ng kg-1) caused marked bronchoconstriction and concomitant hypertension. The cyclooxygenase inhibitors aspirin (5 mg kg-1) and indomethacin (5 mg kg-1) and the thromboxane A2 (TXA2) receptor antagonist BM-13.177 (1 mg kg-1) failed to inhibit the peak bronchoconstrictive response but significantly inhibited the prolonged response following peak response. These inhibitors also attenuated PAF-induced hypertension. On the other hand, the lipoxygenase inhibitors phenidone (10 mg kg-1) and NDGA (5 mg kg-1) and the leukotriene (LT) receptor antagonist FPL-55712 (2 mg kg-1) affected neither bronchoconstriction nor hypertension induced by PAF. However, when aspirin was given in combination with NDGA, phenidone or FPL-55712, the peak and the following prolonged bronchoconstriction were significantly inhibited. The suppression of PAF-induced hypertension by aspirin was not further inhibited by the combination of these inhibitors. These results indicate that in anaesthetized guinea-pigs PAF-induced bronchoconstriction is composed of a dual response, a direct action (peak response) and an indirect action (prolonged response). The latter may be produced by the generation of TXA2 and lipoxygenase products, while PAF-induced hypertension is indirectly mediated by the generation of TXA2. Topics: Animals; Blood Pressure; Bronchial Spasm; Cyclooxygenase Inhibitors; Guinea Pigs; Hypertension; In Vitro Techniques; Leukotriene Antagonists; Leukotrienes; Lipoxygenase; Lipoxygenase Inhibitors; Male; Platelet Activating Factor; Prostaglandin-Endoperoxide Synthases; Thromboxane A2 | 1988 |
A role for inflammatory mediators in airway hyper-responsiveness.
We have demonstrated that PGF2 alpha potentiates airway contraction in vitro and suggested that this response may be mediated by TxA2. We have localized the site of action of PGF2 alpha to a point distal to the parasympathetic ganglion and shown that it is a specific effect since PGD2 produces no similar potentiation. The mechanism of the potentiation may be by a direct alteration in smooth muscle sensitivity induced by TxA2 (Fig. 4). In our previous studies we have been able to induce hyperresponsiveness in vivo (Berend et al., 1986) but no increased responsiveness in vitro (Armour et al., 1987b). In vivo airway hyperresponsiveness may depend on the presence of a mediator like TxA2 which has a short half-life, is produced by continual stimulation of inflammatory cells and which is "washed out" in vitro once the source of stimulation is removed. The fact that we can demonstrate an increase in sensitivity in vitro using PGF2 alpha or a TxA2 analogue, combined with the fact that both mediators are released from a variety of inflammatory cells suggests that one or both of these agents may mediate part of the increased responsiveness observed in asthma. Topics: Animals; Asthma; Bronchi; Bronchial Spasm; Carbachol; Dinoprost; Histamine; Muscle, Smooth; Prostaglandins F; Rabbits; Thromboxane A2; Trachea | 1988 |
Thromboxane A2 and airway responsiveness to acetylcholine aerosol in the conscious primate.
Topics: Acetylcholine; Aerosols; Airway Resistance; Animals; Biphenyl Compounds; Bronchial Spasm; Consciousness; Indoles; Lung Compliance; Prostaglandin Endoperoxides, Synthetic; Saimiri; Thromboxane A2 | 1988 |
Effect of baclofen on different models of bronchial hyperreactivity in the guinea-pig.
In this paper we report an inhibitory effect of (-)-baclofen on many models of bronchial hyperreactivity both in vivo and in vitro. (-)-Baclofen protects guinea-pigs from the anaphylactic bronchospasm induced in sensitized animals by an ovalbumin aerosol and from that induced by aerosols of histamine and PGF2 alpha. Moreover (-)-baclofen reduces the TXA2 and TXB2 output induced by ovalbumin from isolated sensitized guinea-pig lungs. On the other hand (-)-baclofen does not show antihistaminic, anticholinergic or antiprostaglandinic action on isolated tracheal preparations. It is concluded that baclofen can provide protection from bronchial hyperreactivity possibly through a modulation of autonomic nervous system activity. Topics: Acetylcholine; Anaphylaxis; Animals; Baclofen; Bronchial Spasm; Dinoprost; Guinea Pigs; Histamine Antagonists; Lung; Male; Prostaglandins F; Thromboxane A2; Thromboxane B2 | 1987 |
Increased in vitro airway responsiveness in sheep following repeated exposure to antigen in vivo.
We have studied the effect of repeated in vivo antigen exposure on in vitro airway responsiveness in sensitized sheep. Fourteen sheep underwent five biweekly exposures to aerosolized Ascaris suum antigen or saline. Following this exposure regimen, the animals were killed and tracheal smooth muscle and lung parenchymal strips were prepared for in vitro studies of isometric contraction in response to histamine, methacholine, prostaglandin F2 alpha, and a thromboxane A2 analogue. No alteration in tracheal smooth muscle responsiveness was observed between saline- and antigen-exposed tissue. In contrast, by use of lung parenchymal strips as an index of peripheral airway responsiveness, significant increases in responsiveness to histamine and a thromboxane A2 analogue (10(-6) and 10(-5) M) were observed in antigen-exposed tissue compared with saline controls. These results demonstrate that repeated antigen exposure in vivo selectively increase the responsiveness of peripheral lung smooth muscle to certain chemical mediators of anaphylaxis. Topics: Animals; Antigens; Ascaris; Bronchial Spasm; Dinoprost; Histamine; Lung; Methacholine Chloride; Methacholine Compounds; Muscle Contraction; Muscle, Smooth; Prostaglandins F; Respiratory System; Sheep; Thromboxane A2; Trachea | 1985 |
Pharmacological control of thromboxane A2 in lung.
Topics: Animals; Bronchi; Bronchial Spasm; Guinea Pigs; Histamine Release; In Vitro Techniques; Lung; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Receptors, Muscarinic; SRS-A; Thromboxane A2; Thromboxanes | 1981 |
Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives.
Topics: Animals; Aspirin; Blood Platelets; Bronchial Spasm; Epoprostenol; In Vitro Techniques; Lysophosphatidylcholines; Platelet Activating Factor; Platelet Aggregation; Prostaglandins; Rabbits; Thromboxane A2; Time Factors | 1980 |
Bronchoconstriction by histamine and bradykinin in guinea pigs: relationship to thromboxane A2 generation and the effect of aspirin.
Histamine 2.5, 5, 10 or 20 microgram/kg i.v. induce a pronounced bronchospasm in guinea-pigs, accompanied by a dose-related increase of TXA2 in arterial blood, as revealed by contraction of rabbit isolated aorta and by radioimmunoassay. Aspirin 10 mg/kg prevented formation of TXA2-like material without significantly modifying the severity of the bronchospasm. Bradykinin 0.5, 1 or 2 microgram/kg i.v. acted similarly, except that pretreatment with aspirin blocked both the increased airway resistance and release of TXA2. Aspirin also blocked the increase in blood pressure and heart rate caused by histamine or bradykinin. Topics: Acetylcholine; Animals; Aspirin; Blood Pressure; Bradykinin; Bronchial Spasm; Dose-Response Relationship, Drug; Female; Guinea Pigs; Histamine; Male; Pulse; Rabbits; Thromboxane A2; Thromboxanes | 1980 |